This topic contains a solution. Click here to go to the answer

Author Question: A bone marrow aspirate is hypercellular and has an M:E ratio of 1:4. What can be concluded from ... (Read 24 times)

Davideckstein7

  • Hero Member
  • *****
  • Posts: 555
A bone marrow aspirate is hypercellular and has an M:E ratio of 1:4. What can be concluded from this? There is:
 
  a. Myeloid hyperplasia
  b. Myeloid hypoplasia
  c. Erythroid hypoplasia
  d. Erythroid hyperplasia

Question 2

An instrument printout reveals an RDW of 33. Which of the following would best correlate with those results?
 
  a. The presence of a dimorphic cell population on the PB smear
  b. The presence of marked polychromasia on the PB smear
  c. The presence of spherocytes on the PB smear
  d. The presence of macro-ovalocytes on the PB smear



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
Marked as best answer by a Subject Expert

Edwyer

  • Sr. Member
  • ****
  • Posts: 337
Answer to Question 1

Correct Answer: D

Answer to Question 2

Correct Answer: A




Davideckstein7

  • Member
  • Posts: 555
Reply 2 on: Jun 25, 2018
Great answer, keep it coming :)


chereeb

  • Member
  • Posts: 326
Reply 3 on: Yesterday
:D TYSM

 

Did you know?

The first documented use of surgical anesthesia in the United States was in Connecticut in 1844.

Did you know?

ACTH levels are normally highest in the early morning (between 6 and 8 A.M.) and lowest in the evening (between 6 and 11 P.M.). Therefore, a doctor who suspects abnormal levels looks for low ACTH in the morning and high ACTH in the evening.

Did you know?

On average, someone in the United States has a stroke about every 40 seconds. This is about 795,000 people per year.

Did you know?

Though newer “smart” infusion pumps are increasingly becoming more sophisticated, they cannot prevent all programming and administration errors. Health care professionals that use smart infusion pumps must still practice the rights of medication administration and have other professionals double-check all high-risk infusions.

Did you know?

Bisphosphonates were first developed in the nineteenth century. They were first investigated for use in disorders of bone metabolism in the 1960s. They are now used clinically for the treatment of osteoporosis, Paget's disease, bone metastasis, multiple myeloma, and other conditions that feature bone fragility.

For a complete list of videos, visit our video library